Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial

Room for Improvement in the Treatment of Helicobacter pylori Infection

(2021) Olga P. Nyssen et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Impact of antimicrobial resistance rates on eradication of Helicobacter pylori in a United States population

(2021) Erick A. Argueta et al.   GASTROENTEROLOGY

Impact of body size on first‐line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy

(2021) Hiroyuki Eto et al.   HELICOBACTER

National and Regional United States Antibiotic Resistance to Helicobacter pylori Resistance to Helicobacter pylori. Lessons from a Clinical Trial

(2021) Kristina G. Hulten et al.   GASTROENTEROLOGY

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis

(2021) Theodore Rokkas et al.   GASTROENTEROLOGY

Comparison of Culture With Antibiogram to Next-Generation Sequencing Using Bacterial Isolates and Formalin-Fixed, Paraffin-Embedded Gastric Biopsies

(2021) Kristina G. Hulten et al.   GASTROENTEROLOGY

Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study)

(2020) Toshihisa Takeuchi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan

(2020) Sho Suzuki et al.   GUT

Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan

(2020) Takuji Gotoda et al.   JOURNAL OF GASTROENTEROLOGY

European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients

(2020) Olga P Nyssen et al.   GUT

The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth‐based quadruple therapy

(2020) Haoran Ke et al.   HELICOBACTER

Transitioning of Helicobacter pylori Therapy from Trial and Error to Antimicrobial Stewardship

(2020) David Y. Graham   Antibiotics-Basel

Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials

(2019) Qiu-Ju Lyu et al.   Biomed Research International

Retrospective Analysis Confirms Tetracycline Quadruple as Best Helicobacter pylori Regimen in the USA

(2019) Mohd Amer Alsamman et al.   DIGESTIVE DISEASES AND SCIENCES

Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori

(2019) Takahisa Furuta et al.   DIGESTION

Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing

(2019) Daniel Pohl et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

(2018) Nihal El Rouby et al.   Expert Opinion on Drug Metabolism & Toxicology

Prevalence of antibiotic resistance in Helicobacter pylori : a systematic review and meta-analysis in World Health Organization regions

(2018) Alessia Savoldi et al.   GASTROENTEROLOGY

Update on the Use of Vonoprazan: A Competitive Acid Blocker

(2018) David Y. Graham et al.   GASTROENTEROLOGY

Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori

(2018) Min Li et al.   HELICOBACTER

Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori : A multicenter, prospective, randomized trial

(2017) Soichiro Sue et al.   HELICOBACTER

Management of Helicobacter Pylori in the United States: Results from a national survey of gastroenterology physicians

(2017) Traci T. Murakami et al.   PREVENTIVE MEDICINE

Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?

(2017) DavidY Graham et al.   Saudi Journal of Gastroenterology

Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-LineHelicobacter pyloriEradication: A Randomized Controlled Trial

(2017) Masafumi Maruyama et al.   Canadian Journal of Gastroenterology and Hepatology

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker

(2016) Hitomi Yamasaki et al.   XENOBIOTICA

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

First-line eradication forHelicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced byCYP2C19genotype

(2015) Yoshimasa Saito   WORLD JOURNAL OF GASTROENTEROLOGY

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

(2015) Yuuichi Sakurai et al.   Clinical and Translational Gastroenterology

Empiric Quadruple vs. Triple Therapy for Primary Treatment of Helicobacter pylori Infection: Systematic Review and Meta-Analysis of Efficacy and Tolerability

(2009) Jay Luther et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY